GeoVax Labs Inc (GOVX) Stock Analysis
Verdict: AVOID
Extreme cash burn and imminent dilution risk overshadow clinical potential; current $3M cash vs $21M burn is a terminal trajectory.
Investment score: 18/100
Analysis as of
Is GeoVax Labs Inc stock worth reviewing? The TradeMates thesis
GeoVax is a micro-cap biotech with a failing balance sheet and no immediate revenue stream, facing near-certain equity dilution.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 10/100 (weight 15%)
- Earnings Quality: 45/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 20/100 (weight 10%)
- Risk-Adjusted Return: 10/100 (weight 15%)
GeoVax Labs Inc opportunities and risks
What speaks for GOVX
- Phase 2 Clinical Data (COVID-19/Infectious Disease)
What speaks against GOVX
- Terminal Dilution Risk (Primary)
Peers and competitors
- ACXP
- ENSC
- XBIO
- SILO
- HCWB
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| GOVX | n/a | 0.0x | 0.1x | 0.0% | 0.0% | -2515.2% |
| ACXP | n/a | 0.0x | 0.9x | 0.0% | 0.0% | -271.1% |
| ENSC | n/a | 2.5x | n/a | -103.7% | -810.6% | -272.8% |
| XBIO | n/a | 1.7x | 0.9x | 100.0% | -70.0% | -34.3% |
| SILO | n/a | 72.0x | n/a | -328.7% | -6717.4% | -74.0% |
| HCWB | n/a | 0.2x | n/a | 99.2% | -24.7% | -915.1% |
| Peer median | n/a | 1.7x | n/a | 0.0% | -70.0% | -271.1% |
Frequently asked questions about GeoVax Labs Inc (GOVX)
Is GOVX stock a good investment?
The TradeMates model rates GeoVax Labs Inc as AVOID with an investment score of 18/100. GeoVax is a micro-cap biotech with a failing balance sheet and no immediate revenue stream, facing near-certain equity dilution. This is algorithmic model output, not personal investment advice.
Is GOVX stock a buy?
The TradeMates model verdict for GOVX is AVOID with an investment score of 18/100. Treat this as a model signal to review, not a personal buy recommendation.